Form 4: Mineralys Therapeutics' Chief Medical Officer Executes Stock Option and Sells Shares Under 10b5-1 Plan

Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics, Inc. exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On April 14, 2025, David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, Inc., executed a stock option to acquire 6,348 shares of common stock at a price of $1.08 per share.
• Rodman also sold 2,966 shares at a weighted average price of $13.6929, with prices ranging from $13.5382 to $13.8250, and 8,400 shares at a price of $14.83.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on October 25, 2024.
• Following these transactions, Rodman directly owns 111,686 shares of common stock and holds options for 107,926 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 trading plan suggests that the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, David Malcom Rodman, Chief Medical Officer, Form 4, Stock Option, Share Sale, 10b5-1 Trading Plan, Beneficial Ownership, Securities Exchange Act